Increased striatal VMAT2 binding in mice after chronic administration of methcathinone and manganese




Asser A, Kõks S, Snellman A, Haaparanta-Solin M, Arponen E, Grönroos T, Nairismägi J, Bergquist J, Soomets U, Piip P, Eltermaa M, Sauk M, Lindmäe H, Rinne JO, Taba P.

2016

Brain Research

1652

97

102

6

0006-8993

DOIhttps://doi.org/10.1016/j.brainres.2016.09.034



Intravenous use of a psychostimulant drug containing methcathinone
(ephedrone) and manganese causes an irreversible extrapyramidal syndrome
in drug abusers. We aimed to reproduce the syndrome in mice to evaluate
dopaminergic damage. C57/B6 mice were intraperitoneally injected once a
day with the study drug or saline for a period of 27 weeks. Motor
activity was recorded in an automated motility-box. After 13 and 27
weeks of treatment, ex vivo digital autoradiography was performed using [11C]dihydrotetrabenazine ([11C]DTBZ). After 27 weeks of treatment [11C]DTBZ
autoradiography demonstrated a significant increase in the
striatum-to-cerebellum binding ratio compared with saline treated
controls. At the same time point, there was no evident change in motor
activity. Increased [11C]DTBZ binding may indicate vesicular
monoamine transporter type 2 (VMAT2) function is altered. The lack of
extrapyramidal symptoms in animals could be attributed to low dosing
regimen or high metabolic rate.



Last updated on 2024-26-11 at 20:44